Imunon appoints Dr. Stacy R. Lindborg as President and CEO effective May 13

Imunon, Inc.

Employment agreement: $567,000 base salary, 100% target bonus, 225,000 stock options vesting over 4 years, $200,000 sign-on bonus.
Dr. Lindborg brings 30 years of pharma/biotech experience; most recently co-CEO of BrainStorm Cell Therapeutics (BCLI).
Phase 2 OVATION 2 topline results for IMNN-001 (ovarian cancer) expected by mid-summer; Phase 1 COVID-19 vaccine data by year-end.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stacy R. Lindborg

President and Chief Executive Officer

IMNN · Imunon, Inc.

Effective: 2024-05-13
Filed: May 8, 2024, 7:59 PM ET

On May 8, 2024, Imunon, Inc. (the “Company”) announced the appointment of Stacy R. Lindborg, Ph.D., as President and Chief Executive Officer of the Company, effective as of May 13, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stacy R. Lindborg was appointed as President and Chief Executive Officer at Imunon, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On May 8, 2024, Imunon, Inc. (the “Company”) announced the appointment of Stacy R. Lindborg, Ph.D., as President and Chief Executive Officer of the Company, effective as of May 13, 2024.

View on SEC.gov

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.